Urvi Das Sharma

• VSPE Lead for Zegalogue: Ensuring launch readiness of Zegalogue at an affordable price point, to patients across key markets in light of GlucaGen Hypo-kit discontinuation.
• Market Access for In-market Semaglutide in T2D:

i. Development of payer engagement strategies and value tools for FLOW (CKD) and STRIDE (PAD) trials for Ozempic.

ii. Payer Value Tools for SOUL (CVD) for Ryvelsus.

iii. Reinforcing the value of semaglutide in type 2 diabetes.

• Market Access for Pipeline Semaglutide in T2D:

Leading CagriSema's early value proposition, based on subpopulation segmenting for optimal access. Understanding access criteria for premium reimbursable subpopulations. Positioning the value of weight loss in T2D as a key value driver for CagriSema.

• Market access for daily insulins: Regular updates of value tools to sustain daily insulin access.

• Life Cycle Management of Xultophy and Ryzodeg from Global Market Access: Risk grid analysis, budget management, shaping of the Brand Plan, and updating value communication tools to support affiliates in NGI sustenance.
• Early gap analysis for Zegalogue: Development of early access strategy, launch market decisions, key competitor insight analysis, and determination of gap analysis in the Zealand Pharma asset handover.

• Multichannel engagement strategy development to support promotional and non-promotional commercial tools in the field of oncology, vaccines, and biosimilars; developing educational materials for HCPs, patients, and key KOLs.